Business
Calquence significantly prolonged the time patient
Calquence significantly prolonged the time patient.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \nRNS Number : 4350C AstraZeneca PLC 17 June 2019 \n\n17 June 2019 07:00 BST\n\n \nCalquence significantly prolonged the time patients lived without disease progression in relapsed or refractory chronic lymphocytic leukaemia\n \nAn encouraging 88% of patients on Calquence remained free of disease progression after 12 months, vs. 68% of patients on rituximab combined with idelalisib or bendamustine\n \nAstraZeneca today announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association (EHA) Annual Congress in Amsterdam, showing Calquence (acalabrutinib) significantly prolonged the time patients live without disease progression in relapsed or refractory chronic lymphocytic leukaemia (CLL).\n \nThe ASCEND trial compared Calquence with the physician's choice of rituximab combined with idelalisib (IdR) or bendamustine (BR) in patients with relapsed or refractory CLL.\n \nAt a median follow-up of 16.1 months, results from the trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for patients treated with Calquence vs. IdR or BR, reducing the risk of disease progression or death by 69% (HR, 0.31; 95% CI, 0.20-0.49, p<0.0001). The median time without disease progression for patients treated with Calquence has not yet been reached vs. 16.5 months in the control arm. At 12 months, 88% of patients on Calquence showed no disease progression compared to 68% for the control arm. The safety and tolerability of Calquence was consistent with its established profile.\n \nJosé Baselga, Executive Vice President, Oncology R&D said: \"These data add to the growing body of evidence to support the profile of Calquence as a selective BTK inhibitor that offers a chemotherapy-free treatment option with a favourable safety profile in chronic lymphocytic leukaemia, a life-threatening disease. These data, along with our recent positive results from the Phase III ELEVATE-TN trial in previously-untreated chronic lymphocytic leukaemia, will serve as the foundation for regulatory submissions later this year.\"\n \nPaolo Ghia, MD, Professor, Medical Oncology, Università Vita-Salute San Raffaele in Milan, and investigator of the ASCEND trial, said: \"This is the first randomised trial to di...